Analysenzertifikat: AOD-9604, Charge ATOD-05-2304-01
AOD-9604, Charge ATOD-05-2304-01, geprüft vom unabhängigen Labor Analyton Labs, Zertifikat AN-2026-00008 ausgestellt am 22. September 2026: Reinheit 98.80 ± 0.20 % mittels RP-HPLC, 4.22 mg Peptid pro Vial, Trifluoracetat < 20 ppm, bakterielle Endotoxine < 0.05 EU/mg, insgesamt 21 Bestimmungen.
- Produkt
- AOD-9604
- Charge
- ATOD-05-2304-01
- Zertifikatsnummer
- AN-2026-00008
- Labor
- Analyton Labs
- Ausgestellt
- Probe
- AOD-9604, lyophilised powder, vial labelled 5 mg
Zusammenfassung der Ergebnisse, 21 Bestimmungen
Methoden und Ergebnisse sind auf Englisch angegeben, genau so, wie das Labor sie erfasst hat.
| Bestimmung | Methode | Ergebnis | Spezifikation |
|---|---|---|---|
| Appearance | Visual | White to off-white powder | White to off-white powder |
| Purity | RP-HPLC, C18, 214 nm (280 nm control trace), area % | 98.80 ± 0.20 % (k = 2) | >= 98.0 % |
| Related substances | RP-HPLC, 214 nm; LOD 0.01 %, LOQ 0.03 %, reporting threshold 0.05 % | Largest single impurity 0.67 % at RRT 1.03 (± 0.03 %); total impurities 1.20 %, i.e. 0.051 mg per vial | Single <= 1.0 %, total <= 2.0 % |
| Impurity profile | RP-HPLC with LC-HRMS assignment | RRT 0.94, 0.18 %, truncated sequence (des-Tyr); RRT 1.03, 0.67 %, +0.98 Da (deamidation of Gln); RRT 1.18, 0.35 %, twice the mass (dimer through a rearranged disulfide) | Peaks above 0.05 % reported (ICH Q3B) |
| Net peptide content | Amino acid analysis after acid hydrolysis | 86.50 ± 1.2 % w/w (k = 2) | >= 85 % |
| Fill weight | Gravimetric | 4.88 ± 0.05 mg | Labelled 5 mg |
| Peptide per vial | Calculated from fill weight and net peptide content | 4.22 mg per vial labelled 5 mg, i.e. 84.4 % of label | 95 to 105 % of label |
| Vial-to-vial consistency | Gravimetric, two vials of the batch | 4.88 and 5.00 mg, difference 2.5 %; purity of both within 0.1 % | <= 5 % |
| Counter-ion content | Ion chromatography, suppressed conductivity | Acetate 8.50 % w/w (± 0.51 %), i.e. 0.41 mg per vial; 3.0 mol acetate per mol peptide at 2 basic residues and a free N-terminus | <= 12 % |
| Trifluoroacetate | Ion chromatography, LOQ 20 ppm | < 20 ppm; chloride and phosphate below LOQ | <= 1000 ppm |
| Water content | Coulometric Karl Fischer, USP <921> | 4.50 ± 0.23 % w/w (k = 2), i.e. 0.22 mg per vial | <= 8.0 % |
| Mass balance | Peptide + counter-ion + water | 86.50 + 8.50 + 4.50 = 99.50 % (± 1.3 %) | Close to 100 % |
| pH | Potentiometric, 5 mg/ml in water | 5.2 | 4.4 to 6.0 |
| Solubility | Visual, 5 mg/ml and 1 mg/ml | >= 5 mg/ml in water and in bacteriostatic water; clear, colourless, free of particles within 30 s | Clear solution |
| Bacterial endotoxins | Kinetic chromogenic LAL, USP <85> | < 0.05 EU/mg (< 0.24 EU per vial) | <= 10 EU/mg |
| Sterility | Membrane filtration, USP <71>; fluid thioglycollate 30 to 35 °C and soya bean casein digest 20 to 25 °C | No growth after 14 days, 2 vials | No growth |
| Microbial enumeration | Plate method, USP <61> and <62> | TAMC < 10 CFU/g, TYMC < 10 CFU/g; E. coli, Salmonella, S. aureus and P. aeruginosa absent in 1 g | TAMC <= 1000 CFU/g, TYMC <= 100 CFU/g, specified organisms absent |
| Residual solvents | Headspace GC, USP <467> | Acetonitrile 45 ppm; N,N-dimethylformamide, methanol, dichloromethane, diethyl ether, diisopropyl ether and piperidine each < 10 ppm (LOQ 10 ppm) | ICH Q3C: acetonitrile <= 410, DMF <= 880, methanol <= 3000, dichloromethane <= 600, ethers <= 5000 ppm |
| Elemental impurities | ICP-MS after microwave digestion (HNO3/H2O2), USP <233> | Cd, Pb, As, Hg < 0.05 µg/g; Co, V, Ni < 0.10 µg/g, all below LOQ | ICH Q3D(R2) Class 1 and 2A, parenteral PDE |
| Chiral purity (D-amino acids) | Acid hydrolysis (6 M DCl in D2O, 110 °C, 24 h), Marfey's derivatisation (FDAA), LC-MS | D-Cys 0.10 %, D-Ser 0.08 %, D-Phe 0.06 %, D-Tyr 0.05 %, D-Gln 0.05 %, D-Glu 0.05 %, others < 0.05 %; Gly achiral; sum of D-forms 0.47 % | Each D-amino acid <= 0.2 %, sum of D-forms <= 0.5 % |
| Compound screening | LC-HRMS full scan, m/z 100 to 2000, against library: fentanyl and analogues, hGH fragment 176-191 (same sequence without Tyr), tesamorelin, protected intermediates (tBu, Boc, Trt, Pbf, Fmoc), free amino acids | None detected above 0.05 % area | No foreign compound above 0.05 % area |
SHA-256 der Datei: 19d9f0ebd5c348ba467fc2a481201e64dac9e8ac0787f7447747d79cf6dc4fe9
Forschungsmaterial. Das Zertifikat beschreibt die Eigenschaften der Charge, nicht die Eignung für irgendeine Anwendung bei Menschen oder Tieren.
